Testing biomarkers in immunotherapy for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your melanoma diagnosis has been confirmed by lab testing (biopsy/pathology)
- Your melanoma is stage IIID unresectable or stage IV, and it cannot be fully removed with surgery
- Your general functioning is good (ECOG/WHO performance status 0 to 2)
- You are starting your first systemic (whole-body) treatment for melanoma with immunotherapy such as nivolumab, ipilimumab+nivolumab, or pembrolizumab
- You had a CT and PET/CT scan within 4 weeks before starting, and you can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial studies why immunotherapy works better for some people with advanced melanoma. It looks at markers in your blood or tissue to help doctors predict who might benefit most.
This study looks at whether a simple blood test can track how well immunotherapy is working in people with advanced melanoma. It might help doctors see if the treatment is effective earlier than with scans alone.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.